Cochrane · systematic review · CD006491
Mefloquine for preventing malaria during travel to endemic areas
Tickell‐Painter, M, Maayan, N, Saunders, R, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
36
current version
GRADE rated
0
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 36 · 100%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyMefloquine versus atovaquone‐proguanil for preventing malaria in travellers
Population: non‐immune adults and children travelling to or living in malaria‐endemic settings
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical malaria Mefloquine vs atovaquone‐proguanil | no estimate extracted | 2 studies · 1293 participants | Ungraded |
Serious adverse effects Mefloquine vs atovaquone‐proguanil | RR 1.4 [0.08, 23.22] | 4 studies · 3693 participants | Ungraded |
Discontinuation of drug due to adverse effects Mefloquine vs atovaquone‐proguanil | RR 2.86 [1.53, 5.31] | 3 studies · 1438 participants | Ungraded |
Abnormal dreams Mefloquine vs atovaquone‐proguanil | RR 2.04 [1.37, 3.04] | 1 study · 976 participants | Ungraded |
Insomnia Mefloquine vs atovaquone‐proguanil | RR 4.42 [2.56, 7.64] | 1 study · 976 participants | Ungraded |
Anxiety Mefloquine vs atovaquone‐proguanil | RR 6.12 [1.82, 20.66] | 1 study · 976 participants | Ungraded |
Depressed mood Mefloquine vs atovaquone‐proguanil | RR 5.78 [1.71, 19.61] | 1 study · 976 participants | Ungraded |
Abnormal thoughts or perceptions Mefloquine vs atovaquone‐proguanil | RR 1.5 [0.3, 7.42] | 3 studies · 2433 participants | Ungraded |
Nausea Mefloquine vs atovaquone‐proguanil | RR 2.72 [1.52, 4.86] | 1 study · 976 participants | Ungraded |
Vomiting Mefloquine vs atovaquone‐proguanil | RR 1.31 [0.49, 3.5] | 1 study · 976 participants | Ungraded |
Abdominal pain Mefloquine vs atovaquone‐proguanil | RR 0.9 [0.52, 1.56] | 1 study · 976 participants | Ungraded |
Diarrhoea Mefloquine vs atovaquone‐proguanil | RR 0.94 [0.6, 1.47] | 1 study · 976 participants | Ungraded |
Headache Mefloquine vs atovaquone‐proguanil | RR 1.72 [0.99, 2.99] | 1 study · 976 participants | Ungraded |
Dizziness Mefloquine vs atovaquone‐proguanil | RR 3.99 [2.08, 7.64] | 1 study · 976 participants | Ungraded |
Pruritis Mefloquine vs atovaquone‐proguanil | RR 1.28 [0.6, 2.7] | 1 study · 976 participants | Ungraded |
Visual impairment Mefloquine vs atovaquone‐proguanil | RR 2.04 [0.88, 4.73] | 1 study · 976 participants | Ungraded |
Mouth ulcers Mefloquine vs atovaquone‐proguanil | RR 1.45 [0.7, 3] | 1 study · 976 participants | Ungraded |
Mefloquine versus doxycycline for preventing malaria in travellers
Population: Non‐immune adults and children travelling to malaria‐endemic settings
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical malaria Mefloquine vs doxycycline | RR 1.35 [0.35, 5.19] | 4 studies · 744 participants | Ungraded |
Serious adverse effects Mefloquine vs doxycycline | RR 1.53 [0.23, 10.24] | 3 studies · 3722 participants | Ungraded |
Discontinuations due to adverse effects Mefloquine vs doxycycline | RR 1.08 [0.41, 2.87] | 4 studies · 763 participants | Ungraded |
Abnormal dreams Mefloquine vs doxycycline | RR 10.49 [3.79, 29.1] | 4 studies · 2588 participants | Ungraded |
Insomnia Mefloquine vs doxycycline | RR 4.14 [1.19, 14.44] | 4 studies · 3212 participants | Ungraded |
Anxiety Mefloquine vs doxycycline | RR 18.04 [9.32, 34.93] | 3 studies · 2559 participants | Ungraded |
Depressed mood Mefloquine vs doxycycline | RR 11.43 [5.21, 25.07] | 2 studies · 2445 participants | Ungraded |
Abnormal thoughts or perceptions Mefloquine vs doxycycline | RR 6.6 [0.92, 47.2] | 2 studies · 2445 participants | Ungraded |
Nausea Mefloquine vs doxycycline | RR 0.37 [0.3, 0.45] | 5 studies · 2683 participants | Ungraded |
Vomiting Mefloquine vs doxycycline | RR 0.18 [0.12, 0.27] | 4 studies · 5071 participants | Ungraded |
Abdominal pain Mefloquine vs doxycycline | RR 0.3 [0.09, 1.07] | 3 studies · 2536 participants | Ungraded |
Diarrhoea Mefloquine vs doxycycline | RR 0.28 [0.11, 0.73] | 5 studies · 5104 participants | Ungraded |
Dyspepsia Mefloquine vs doxycycline | RR 0.26 [0.09, 0.74] | 5 studies · 5104 participants | Ungraded |
Headache Mefloquine vs doxycycline | RR 1.21 [0.5, 2.92] | 5 studies · 3320 participants | Ungraded |
Dizziness Mefloquine vs doxycycline | RR 3.49 [0.88, 13.75] | 5 studies · 2633 participants | Ungraded |
Visual impairment Mefloquine vs doxycycline | RR 2.37 [1.41, 3.99] | 2 studies · 1875 participants | Ungraded |
Pruritis Mefloquine vs doxycycline | RR 0.52 [0.3, 0.91] | 2 studies · 1794 participants | Ungraded |
Photosensitivity Mefloquine vs doxycycline | RR 0.08 [0.05, 0.11] | 2 studies · 1875 participants | Ungraded |
Vaginal thrush Mefloquine vs doxycycline | RR 0.1 [0.06, 0.16] | 1 study · 1761 participants | Ungraded |
Atovaquone‐proguanil compared to Mefloquine for Non immune child and adult travellers
Population: Non immune child and adult travellers
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Any adverse effect Atovaquone‐proguanil vs Mefloquine | RR 0.72 [0.6, 0.85] | 1 study · 976 participants | Low Downgraded: imprecision, indirectness |
Gastrointestinal adverse effect Atovaquone‐proguanil vs Mefloquine | RR 0.54 [0.42, 0.7] | 1 study · 976 participants | Low Downgraded: risk of bias, indirectness |
Neuropsychiatric adverse event Atovaquone‐proguanil vs Mefloquine | RR 0.86 [0.75, 0.99] | 1 study · 317 participants | Moderate Downgraded: indirectness |
Neuropsychiatric adverse effect Atovaquone‐proguanil vs Mefloquine | RR 0.49 [0.38, 0.63] | 1 study · 976 participants | Low Downgraded: risk of bias, indirectness |
Total Mood Disturbance (TMD) scores Scale from: ‐20 to 108. Atovaquone‐proguanil vs Mefloquine | no estimate extracted | 1 study · 119 participants | Low Downgraded: risk of bias, indirectness |
Doxycycline compared to Mefloquine for Non Immune Child and Adult Travellers
Population: Non Immune Child and Adult Travellers
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Neuropsychiatric adverse event Doxycycline vs Mefloquine | RR 0.84 [0.73, 0.96] | 2 studies · 441 participants | Low Downgraded: imprecision, indirectness |
Any standard drugs compared to Chloroquine‐proguanil for Non Immune Child and Adult Travellers
Population: Non Immune Child and Adult Travellers
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Any adverse effect Any standard drugs vs Chloroquine‐proguanil | RR 0.84 [0.73, 0.96] | 3 studies · 1530 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Gastrointestinal adverse effect Any standard drugs vs Chloroquine‐proguanil | RR 0.71 [0.6, 0.85] | 3 studies · 1530 participants | Very low Downgraded: risk of bias, imprecision, indirectness |